Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers
Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, compared with chemotherapy alone, according to interim data from the CheckMate-649 Phase 3 trial. Notably, survival benefits were seen across several patient groups, regardless of … Continue reading Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed